Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ibritumomab tiuxetan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Ibritumomab tiuxetan. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000222-51 Sponsor Protocol Number: 06_DOG05_44 Start Date*: 2007-09-07
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: Short CHemo RadioImmunotherapy in Follicular Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma
    Medical condition: Follicular Lymphoma First and second relapse of Follicular Lymphoma grade 1, 2, 3a.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006808-11 Sponsor Protocol Number: Studio Zevalin Start Date*: 2006-08-11
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
    Full Title: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.
    Medical condition: Patients with untreated follicular non-Hodgkin's lymphoma grade 1 or 2 according to REAL classification.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061170 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000699-41 Sponsor Protocol Number: Z 0105 Start Date*: 2005-04-05
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE
    Full Title: Multicentric Pilot Phase II Study for use of Fludarabine plus Cyclophosphamide Followed by 90 Y-Ibritumomab Tiuxetan Zevalin in the Treatment of non-Follicular Indolent Lymphomas Refractory or Re...
    Medical condition: Treatment patients with non-Follicular Indolent Lymphomas Refractory or Relapsed after Conventional Front-Line Chemotherapy not Containing Fludarabine and Ciclofosfamide
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007083-28 Sponsor Protocol Number: HOVON85NHL Start Date*: 2008-06-18
    Sponsor Name:HOVON foundation
    Full Title: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partia...
    Medical condition: Aggressive B-cell NHL
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-004349-16 Sponsor Protocol Number: Start Date*: 2005-11-18
    Sponsor Name:GELA Group
    Full Title: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined ...
    Medical condition: Low grade B-cell lymphoma CD20 positive: -Marginal zone -Lymphocytic -Follicular
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003198-22 Sponsor Protocol Number: GELTAMO-Z-BEAM LDCGB Start Date*: 2007-11-14
    Sponsor Name:GELTAMO (Grupo Español de Linfomas y Trasplante autólogo de Médula Ósea)
    Full Title: Trasplante autologo de progenitores hemopoyéticos con acondicionamiento que incluye Zevalin + BEAM en pacientes con linfoma difuso de célula grande B refractario
    Medical condition: Pacientes con linfoma no-Hodgkin difuso de célula grande B, según clasificación OMS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004916-51 Sponsor Protocol Number: SPI-ZEV-11-301 Start Date*: 2012-07-27
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell L...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) BE (Completed) PT (Completed) NL (Completed) AT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000598-31 Sponsor Protocol Number: 06_DOG05_33 Start Date*: 2006-12-14
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma
    Medical condition: Follicular lymphoma LLT Follicle centre lymphoma, follicular grade I, II, III PT Follicle centre lymphoma, follicular grade I, II, III MedDRA Version 9
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006179-19 Sponsor Protocol Number: 2006/27 Start Date*: 2007-03-27
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: ETUDE INTERNATIONALE DE PHASE II EVALUANT UNE ASSOCIATION CHOP-RITUXIMAB AVEC CONSOLIDATION PRECOCE PAR IBRITUMOMAB-TIUXETAN-Y90 CHEZ DES PATIENTS AGES DE 65 ANS A 80 ANS ATTEINTS D'UN LYMPHOME MAL...
    Medical condition: Le lymphome non hodgkinien (LNH) de type folliculaire est une maladie incurable à un stade avancé. Il se caractérise par des rechutes fréquentes succédant à des rémissions de plus en plus rares et ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025310 Lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003539-22 Sponsor Protocol Number: ZETAL 07 Start Date*: 2007-11-08
    Sponsor Name:GIMURELL
    Full Title: Two repeated doses of Yttrium-90 labeled Ibritumomab-Tiuxetan (Zevalin) as salvage treatment for patients with relapsed or refractory aggressive B-cell lymphoma: a phase II study.
    Medical condition: Patients with B-DLCL relapsed or refractory after first line of therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012821 Diffuse large B-cell lymphoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003091-19 Sponsor Protocol Number: GOTEL-FL1LC-0701 Start Date*: 2007-11-14
    Sponsor Name:GOTEL (Grupo Oncológico para el Tratamiento y Estudio de Los linfomas)
    Full Title: "Tratamiento de consolidación con Y90-Ibritumomab Tiuxetan en Pacientes con Linfoma Folicular de Alto Riesgo, en respuesta parcial o completa a Quimioterapia de Inducción con R-CHOP"
    Medical condition: Linfoma Folicular CD20+, grado 1-3a, según la clasificación de la OMS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003302-10 Sponsor Protocol Number: GELTAMO- Z-RIC - Allo Start Date*: 2007-11-14
    Sponsor Name:GELTAMO (Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea)
    Full Title: Trasplante alogénico de progenitores hematopoyéticos tras acondicionamiento no mieloablativo con melfalan ,fludarabina y zevalin en pacientes con linfoma No Hodgkin B agresivo
    Medical condition: Linfoma no Hodgkin de células B, CD20+, agresivo (linfoma difuso de células grandes, linfoma de células del manto, linfoma de células B transformado), de alto riesgo, con indicación de trasplante a...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002211-92 Sponsor Protocol Number: 75/2004/U/Sper Start Date*: 2004-07-06
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Efficacy and safety of subsequent treatment with 90Y-Zevalin in patients with stage II to IV follicular non-Hodgkin?s lymphoma in partial or complete remission after oral fludarabine and mitoxantro...
    Medical condition: Remission induced (CR or PR) stage II to IV follicular non-Hodgkin?s lymphoma patients.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003904 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004851-39 Sponsor Protocol Number: 109/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DI...
    Medical condition: DIFFUSE LARGE BCELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001768-31 Sponsor Protocol Number: ZENO-01 Start Date*: 2012-09-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: MALT Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001727-11 Sponsor Protocol Number: 307940 / 106-20 Start Date*: 2006-03-17
    Sponsor Name:Schering AG, Global Medical Development
    Full Title: A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) ...
    Medical condition: Diffuse large B-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000270-23 Sponsor Protocol Number: Z BEAM 2 Start Date*: 2007-05-21
    Sponsor Name:GELA
    Full Title: TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WI...
    Medical condition: Diffuse Large B cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006601-25 Sponsor Protocol Number: ZAR2007 Start Date*: 2008-03-06
    Sponsor Name:FUNDACION PETHEMA
    Full Title: Estudio abierto, multicéntrico, aleatorizado en fase II, para evaluar la eficacia de tratamiento tras la respuesta terapéutica inicial al régimen R-CHOP en pacientes con linfoma folicular no tratad...
    Medical condition: Linfoma folicular en pacientes no tratados previamente
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002003-17 Sponsor Protocol Number: 200427 Start Date*: 2005-07-18
    Sponsor Name:Rikshospitalet-Radiumhospitalet HF
    Full Title: High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patient...
    Medical condition: Mantle cell lymphoma is a non-Hodgkin lymphoma which is rare and holds a bad prognosis with no known curative therapies available. The lymphoma is most often disseminated at diagnosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Ongoing) DK (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005216-24 Sponsor Protocol Number: DSHNHL2005-1 Start Date*: 2009-06-09
    Sponsor Name:University of Saarland
    Full Title: 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to...
    Medical condition: Relapse or primary progress of aggressive CD-20-positive-B-NHL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:58:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA